Connecticut Innovations announced it has partnered with a global startup accelerator program aimed at supporting early-stage biotechs.
Connecticut Innovations, the state’s quasi-public venture arm, announced it has partnered with a global startup accelerator program aimed at supporting early-stage biotechnology companies.
The program is run by Mission BioCapital, a life sciences venture firm that launched its Platinum Program in 2022 to help biotech startups access funding, lab space and industry expertise.
Applications for the 2026 program are being accepted through May 15, with selected companies to be announced this summer.
Participating startups, which can come from around the world, may receive up to $500,000 in pre-seed funding from program sponsors, including Connecticut Innovations. Companies selected for the program are also guaranteed a lab bench in one of Mission BioCapital’s affiliated incubators; in Connecticut, that includes BioLabs facilities in New Haven.
BioLabs operates shared laboratory and office space for early-stage companies, including a 48,000-square-foot facility at 101 College St. that primarily serves as incubation space for startups.
Additional support in the program includes drug discovery services, legal and intellectual property guidance, and mentorship from industry professionals.
Since launching in 2022, the Platinum Program has supported 24 startups and deployed about $11.5 million in pre-seed funding, according to Mission BioCapital.
Connecticut Innovations said it will also connect participating companies with research institutions, industry operators and potential follow-on funding sources in Connecticut.
